



MEDIGARD LIMITED  
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia  
Telephone +61 7 5578 7822; Fax +61 7 5528 4459  
E-mail: [office@medigard.com.au](mailto:office@medigard.com.au) [www.medigard.com.au](http://www.medigard.com.au)  
ABN 49 090 003 044

## ASX Announcement

Dear Medigard Shareholder

### **New Technology Management and Commercialisation Program**

The Company is pleased to announce that it has signed a commercial agreement with Bio-Link Australia Pty Ltd (Bio-Link) (<http://bio-link.com>) to assist Medigard with a new technology management and commercialisation program, to identify, manage and commercialise new products to augment our existing syringe technology partnered with Sol-Millennium.

Established since 2005, Bio-Link has built a team of experienced biotechnology and medical science professionals and a track-record of technology commercialisation, with strong connections to researchers and the life sciences industry within Australia and overseas.

The Technology Management and Commercialisation Program to be jointly conducted by Medigard and Bio-Link aims to extend Medigard's capabilities into selected medical-related research, intellectual property development and commercialisation.

Executive Director Dr Ian Dixon said "The Technology Management and Commercialisation Program with Bio-Link is a natural step in Medigard's role as an innovator in medical products. In this program we will progress selected R&D projects to the point of proof-of-concept relatively quickly and without spending large amounts of money. Subsequently we will fund worthy projects with the intention of new patents and a clear development pathway. Our aim is to build a pipeline of projects that build value in Medigard across a portfolio of medical technologies/products."

Bio-Link Executive Director Christopher Boyer said "The Bio-Link team is excited to join Dr Dixon and the Medigard team to identify, manage and commercialise innovative and value-adding medical-related technologies. Projects will be selected from our existing portfolio and other sources, based on medical needs and technology opportunities we identify – using members of our expert team and our relationships across Australia and beyond."

Dr Chris Bishop (Chairman of Medigard) said "The Technology Management and Commercialisation Program with Bio-Link is in line with the strategic-intent the Board of Medigard communicated to Shareholders in 2017 and will see Medigard build upon its foundations as an innovator in medical technologies that help both patients and treating professionals".

Under the Consulting Agreement with Bio-Link, Medigard will pay Bio-Link consulting fees and all new intellectual property arising from the program will be owned by Medigard. The Board of Medigard will have oversight of the Program and will ensure projects go through regular reviews and assessments.

### **Share Purchase Plan (SPP) from December 2017**

In addition, the Board of Medigard is pleased to confirm that the December 2017 Share Purchase Plan raised a total of \$363,000 by the sale of 18,300,000 shares at 2 cents per share to existing shareholders. The SPP has been a success despite the short duration available to us prior to Christmas. The company presently has around 118m shares on issue and cash of around \$400,000.

As per previous advices, executives of the company participated in a placement prior to Christmas. These funds remain in the Company as a loan until shareholder approval has been obtained for the issue of shares as per the terms of the placements made by sophisticated investors. If approved, this will result in the issue of a further 10 million shares.

We expect to hold a general meeting of shareholders in July 2018.

The normal notices will be sent out to all shareholders and attendance is encouraged.

Please feel free to contact me any time at [ian.dixon@medigard.com.au](mailto:ian.dixon@medigard.com.au) phone + 613 9894 4555 (local 03 9894 4555) or mobile 0418 561 907.

Yours sincerely

Ian Dixon  
Executive Director  
29<sup>th</sup> May 2018

### About Bio-Link Australia Pty Ltd

Bio-Link Australia is a privately-owned, specialist life sciences business development company with offices in Melbourne and Sydney, Australia. Its clients include leading Australian and international biotech, medical device and diagnostics companies and medical research institutions who engage Bio-Link to provide strategic consulting, business development, scouting and commercialisation services. Bio-Link consists of a team of well-credentialed and experienced business development professionals with a strong track record of facilitating and executing life sciences commercial transactions throughout the world.